{"id":"treatment-regimens-for-mdr-tb","safety":{"commonSideEffects":[{"rate":null,"effect":"Ototoxicity (hearing loss)"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Arthralgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Multi-drug resistant tuberculosis (MDR-TB) requires combination therapy using second-line agents such as fluoroquinolones, injectable aminoglycosides, and other drugs that target different bacterial pathways. These regimens are designed to prevent further resistance development and achieve bacterial clearance in patients whose infections are resistant to first-line TB drugs (isoniazid and rifampicin).","oneSentence":"MDR-TB treatment regimens combine multiple anti-tuberculous drugs to overcome drug resistance and eliminate Mycobacterium tuberculosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:14:11.881Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multi-drug resistant tuberculosis (MDR-TB)"}]},"trialDetails":[{"nctId":"NCT05586230","phase":"PHASE1","title":"Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-03","conditions":"Tuberculosis, Rifampicin Resistant Tuberculosis","enrollment":72},{"nctId":"NCT03057756","phase":"","title":"Treatment of Tuberculosis Multidrug Resistance Treatment of Tuberculosis Multidrug Resistance","status":"COMPLETED","sponsor":"Centre de Recherche Médicale de Lambaréné","startDate":"2015-09-11","conditions":"Multi-drug Resistant Tuberculosis","enrollment":23},{"nctId":"NCT07477119","phase":"PHASE4","title":"Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment","status":"NOT_YET_RECRUITING","sponsor":"Marco Schiuma","startDate":"2026-03","conditions":"Linezolid, Tuberculosis Multi Drug Resistant Active, Therapeutic Drug Monitoring (TDM)","enrollment":150},{"nctId":"NCT02354014","phase":"PHASE2","title":"Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2016-05-03","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":60},{"nctId":"NCT07209761","phase":"PHASE3","title":"A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2025-10-16","conditions":"Pulmonary Tuberculosis","enrollment":532},{"nctId":"NCT07393438","phase":"PHASE2","title":"Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2026-02-21","conditions":"Multidrug-Resistant Tuberculosis, Rifampicin-resistant Tuberculosis, MDR-TB","enrollment":120},{"nctId":"NCT06441006","phase":"PHASE2, PHASE3","title":"Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-10-03","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR","enrollment":400},{"nctId":"NCT07191834","phase":"","title":"A Study on the Short - Course Treatment Regimen Containing Pretomanid for Diabetes Mellitus Complicated With Rifampicin - Resistant/Multidrug - Resistant Pulmonary Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Pulmonary Hospital","startDate":"2025-09-30","conditions":"Rifampicin-resistant/Multidrug-resistant Pulmonary Tuberculosis, Type 2 Diabetes Mellitus (T2DM), Pretomanid","enrollment":60},{"nctId":"NCT02333799","phase":"PHASE3","title":"A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2015-03","conditions":"Pulmonary Tuberculosis","enrollment":109},{"nctId":"NCT05824871","phase":"PHASE3","title":"A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients","status":"RECRUITING","sponsor":"Shanghai Jiatan Pharmatech Co., Ltd","startDate":"2022-09-02","conditions":"Rifampin-Resistant Pulmonary Tuberculosis, Tuberculosis, Multidrug-Resistant (MDR-TB)","enrollment":450},{"nctId":"NCT03141060","phase":"PHASE1, PHASE2","title":"Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-01-30","conditions":"Tuberculosis, HIV Infections","enrollment":37},{"nctId":"NCT05633056","phase":"NA","title":"An Adaptive Randomized Controlled Trial","status":"RECRUITING","sponsor":"Columbia University","startDate":"2023-03-07","conditions":"Multi Drug Resistant Tuberculosis, HIV Infections","enrollment":360},{"nctId":"NCT03828201","phase":"PHASE2","title":"Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB","status":"RECRUITING","sponsor":"Boston University","startDate":"2022-06-07","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":220},{"nctId":"NCT05081401","phase":"PHASE3","title":"Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2022-05-23","conditions":"Multidrug Resistant Tuberculosis, Rifampicin Resistant Tuberculosis, Pre-XDR-TB","enrollment":1050},{"nctId":"NCT05971602","phase":"PHASE2","title":"Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis","status":"TERMINATED","sponsor":"Gates Medical Research Institute","startDate":"2023-07-26","conditions":"Pulmonary Tuberculosis","enrollment":93},{"nctId":"NCT03896685","phase":"PHASE3","title":"Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)","status":"COMPLETED","sponsor":"Médecins Sans Frontières, France","startDate":"2020-04-06","conditions":"Tuberculosis, Multidrug-Resistant, Tuberculosis, Pulmonary Tuberculoses","enrollment":323},{"nctId":"NCT02754765","phase":"PHASE3","title":"Evaluating Newly Approved Drugs for Multidrug-resistant TB","status":"COMPLETED","sponsor":"Médecins Sans Frontières, France","startDate":"2016-12","conditions":"Tuberculosis, Multidrug-Resistant, Infection, Bacterial, Pulmonary Tuberculoses","enrollment":754},{"nctId":"NCT02619994","phase":"PHASE2","title":"Treatment Shortening of MDR-TB Using Existing and New Drugs","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2016-01","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":214},{"nctId":"NCT05871489","phase":"","title":"Strengthening Evidence on Optimal Multidrug-resistant Tuberculosis Treatment Regimens","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harvard Medical School (HMS and HSDM)","startDate":"2020-09-22","conditions":"Tuberculosis, Multidrug-Resistant, HIV","enrollment":800},{"nctId":"NCT04717908","phase":"NA","title":"Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2021-01-20","conditions":"Multidrug Resistant Tuberculosis","enrollment":89},{"nctId":"NCT03867136","phase":"PHASE4","title":"Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2020-06-01","conditions":"Multidrug Resistant Tuberculosis","enrollment":354},{"nctId":"NCT06674291","phase":"","title":"Registry on the Effectiveness and Safety of the 9-month MDR-END Treatment Regimen in Korean Patients with FQ-sensitive MDR-TB (MDR-END Registry)","status":"NOT_YET_RECRUITING","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2024-11-30","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":222},{"nctId":"NCT02589782","phase":"PHASE2, PHASE3","title":"Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)","status":"COMPLETED","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2017-01","conditions":"Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis, Tuberculosis, Pulmonary","enrollment":552},{"nctId":"NCT04207112","phase":"PHASE2, PHASE3","title":"Economic Evaluation of New MDR TB Regimens","status":"COMPLETED","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2020-10-20","conditions":"Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis, Pulmonary Tuberculoses","enrollment":73},{"nctId":"NCT05381194","phase":"PHASE4","title":"BPaL(M) Regimen for the Treatment of MDR/RR-TB","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2022-12-13","conditions":"Multidrug- and Rifampicin-resistant Tuberculosis","enrollment":80},{"nctId":"NCT06224036","phase":"PHASE2","title":"Clinical Study of JDB0131 Benzenesulfonate Tablets in Patients With Drug-sensitive Pulmonary Tuberculosis","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2023-10-31","conditions":"Drug-resistant Tuberculosis","enrollment":52},{"nctId":"NCT05040126","phase":"PHASE3","title":"Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in India","status":"UNKNOWN","sponsor":"Tuberculosis Research Centre, India","startDate":"2021-10-07","conditions":"Pre-Extensively Drug-Resistant Pulmonary TB, Treatment Intolerant Multidrug-Resistant Pulmonary TB, Non-responsive Multidrug-Resistant Pulmonary TB","enrollment":400},{"nctId":"NCT05926466","phase":"PHASE2","title":"BTZ-043 Dose Evaluation in Combination and Selection","status":"UNKNOWN","sponsor":"Michael Hoelscher","startDate":"2023-09-21","conditions":"Tuberculosis, Pulmonary, Other Specified Pulmonary Tuberculosis","enrollment":90},{"nctId":"NCT02409290","phase":"PHASE3","title":"The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB","status":"COMPLETED","sponsor":"IUATLD, Inc","startDate":"2016-03","conditions":"MDR-TB","enrollment":588},{"nctId":"NCT05007795","phase":"NA","title":"Test to Treat TB: Impact of Sputum Sequencing-guided Individualised Therapy on Outcomes in Drug-resistant Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"University of Cape Town","startDate":"2023-07","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":280},{"nctId":"NCT01918397","phase":"PHASE2","title":"Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB","status":"COMPLETED","sponsor":"Boston University","startDate":"2015-01","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":111},{"nctId":"NCT05555303","phase":"PHASE2","title":"Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Multidrug-resistant Tuberculosis","status":"UNKNOWN","sponsor":"Rwanda Biomedical Centre","startDate":"2023-03-01","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":20},{"nctId":"NCT05306223","phase":"PHASE4","title":"A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2022-05-10","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":212},{"nctId":"NCT05493267","phase":"PHASE4","title":"A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB","status":"RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2022-08-03","conditions":"MDR-TB, Immunotherapy","enrollment":30},{"nctId":"NCT04421495","phase":"PHASE4","title":"Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2020-07-16","conditions":"Multidrug Resistant Tuberculosis","enrollment":608},{"nctId":"NCT03259269","phase":"","title":"Expand New Drugs for TB [endTB]","status":"COMPLETED","sponsor":"Partners in Health","startDate":"2015-04-01","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":2804},{"nctId":"NCT02583048","phase":"PHASE2","title":"Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-08-15","conditions":"Tuberculosis, HIV Infections","enrollment":84},{"nctId":"NCT00685360","phase":"PHASE2","title":"A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2008-05-08","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug Resistant, Extensively Drug-Resistant Tuberculosis","enrollment":481},{"nctId":"NCT01131351","phase":"PHASE2","title":"Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-02-19","conditions":"Tuberculosis","enrollment":10},{"nctId":"NCT02573350","phase":"PHASE2","title":"A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2009-03-26","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":213},{"nctId":"NCT02454205","phase":"PHASE2, PHASE3","title":"An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2015-11-12","conditions":"Tuberculosis, Multidrug Resistant Tuberculosis, Extensively-drug Resistant Tuberculosis","enrollment":154},{"nctId":"NCT01859923","phase":"PHASE2","title":"A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2013-07-20","conditions":"Multidrug Resistant Tuberculosis","enrollment":37},{"nctId":"NCT03604848","phase":"NA","title":"NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2018-08-05","conditions":"Multidrug Resistant Tuberculosis","enrollment":488},{"nctId":"NCT01856634","phase":"PHASE1","title":"Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2013-06-14","conditions":"Multidrug Resistant Tuberculosis, Pediatric","enrollment":37},{"nctId":"NCT02975570","phase":"PHASE3","title":"Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin","status":"WITHDRAWN","sponsor":"Boston University","startDate":"2017-08","conditions":"Tuberculosis Multi Drug Resistant Active","enrollment":""},{"nctId":"NCT03069534","phase":"PHASE2, PHASE3","title":"Study of Adjunctive Recombinant Human Interleukin-2 Therapy in Patients With MDR-TB","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2009-06-01","conditions":"MDR TB","enrollment":500},{"nctId":"NCT01509508","phase":"NA","title":"Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2012-03","conditions":"HIV Infection","enrollment":28153},{"nctId":"NCT00727844","phase":"PHASE2","title":"Linezolid to Treat Extensively-Drug Resistant Tuberculosis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07","conditions":"Pulmonary Tuberculosis, Multidrug Resistant Tuberculosis, Extensively Drug Resistant Tuberculosis","enrollment":41},{"nctId":"NCT01618422","phase":"NA","title":"Directly Observed Therapy Short Course-Plus Versus DOTS for Retreatment of Relapsed Pulmonary Tuberculosis in Guangzhou","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2009-03","conditions":"Pulmonary Tuberculosis","enrollment":225},{"nctId":"NCT01600963","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis","status":"WITHDRAWN","sponsor":"Janssen Infectious Diseases BVBA","startDate":"2014-03","conditions":"Multi-drug Resistant Tuberculosis","enrollment":""},{"nctId":"NCT02496572","phase":"","title":"Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan","status":"UNKNOWN","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2013-09","conditions":"Multidrug Resistant Tuberculosis","enrollment":110},{"nctId":"NCT00910871","phase":"PHASE2","title":"To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.","status":"COMPLETED","sponsor":"Janssen Infectious Diseases BVBA","startDate":"2009-09","conditions":"Tuberculosis","enrollment":241},{"nctId":"NCT00449644","phase":"PHASE2","title":"TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).","status":"COMPLETED","sponsor":"Janssen Infectious Diseases BVBA","startDate":"2007-06","conditions":"Tuberculosis","enrollment":208},{"nctId":"NCT02120638","phase":"PHASE3","title":"Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2014-04","conditions":"Multidrug Resistant Tuberculosis","enrollment":100},{"nctId":"NCT00513396","phase":"PHASE2, PHASE3","title":"High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis","status":"COMPLETED","sponsor":"GSVM Medical College","startDate":"2004-01","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":134}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1392,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Treatment regimen for MDR-TB using WHO guidelines"],"phase":"marketed","status":"active","brandName":"Treatment regimens for MDR-TB","genericName":"Treatment regimens for MDR-TB","companyName":"Shanghai Pulmonary Hospital, Shanghai, China","companyId":"shanghai-pulmonary-hospital-shanghai-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MDR-TB treatment regimens combine multiple anti-tuberculous drugs to overcome drug resistance and eliminate Mycobacterium tuberculosis. Used for Multi-drug resistant tuberculosis (MDR-TB).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}